SEC Filing Analysis: USANA HEALTH SCIENCES INC (USNA)

Executive Summary

• Trading Significance: Medium
• Key Takeaway: Pzena Investment Management, a respected value-investing firm, has filed an amendment to its Schedule 13G, disclosing a passive beneficial ownership of 1,212,588 shares, or 6.6% of USANA Health Sciences Inc.'s common stock, as of September 30, 2025.
• Market Impact: The filing indicates continued significant institutional ownership, which is generally a neutral to positive signal. As this is an amendment to a passive stake, the immediate market impact is expected to be minimal unless the change from the prior filing is substantial.

Company Information

Field	Value
Company	USANA HEALTH SCIENCES INC
Ticker Symbol	USNA
CIK	0000896264
Industry	Medicinal Chemicals & Botanical Products [2833]

Insider Information

Field	Value
Name	PZENA INVESTMENT MANAGEMENT LLC
CIK	0001027796
Title/Position	Not Applicable (Institutional Filer)
Relationship	Investment Adviser (IA)

Transaction Details

This filing is a Schedule 13G/A, which reports an institution's beneficial ownership stake as of a specific date, rather than a specific transaction.

Field	Value
Form Type	SCHEDULE 13G/A
Event Date	2025-09-30
Transaction Code	Not Applicable
Security Type	Common Stock
Shares Beneficially Owned	1,212,588
Percent of Class	6.6%
Total Value	Not Applicable
Shares Owned After	1,212,588
Ownership Type	Indirect (Held on behalf of clients)

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral to Slightly Positive
• Reasoning: The continued holding of a significant 6.6% stake by a well-known value investment firm like Pzena lends credibility to the company's long-term value proposition. However, the passive nature of the stake (Rule 13d-1(b)) and the fact that this is an amendment (not a new position) will likely temper any strong market reaction.

Volume & Sentiment

• Expected Volume Impact: Low. 13G filings typically do not drive significant trading volume.
• Sentiment Indicator: Bullish. The maintenance of a large position by a sophisticated investor is a bullish signal for the long-term outlook of the stock.

Investment Insights

Positive Market Indicators

• Institutional Confidence: A respected firm like Pzena maintaining a stake above the 5% reporting threshold indicates a belief in the company's underlying value.
• Passive Stake: The filing certifies that the stake is not held for the purpose of changing or influencing control of the company, which reduces the risk of a hostile or activist situation.

Risk Factors

• Amendment Nature: Without comparing this to the previous filing, the direction of the change (increase or decrease in shares) is unknown. A decrease could be a negative signal.
• Passive Investor: As a passive investor, Pzena could decide to reduce its position at any time without the same immediate disclosure requirements as a corporate insider.

Key Takeaways

1. Pzena Investment Management continues to be a major shareholder in USANA Health Sciences with a 6.6% stake.
2. The filing is under Schedule 13G, confirming the passive nature of the investment.
3. This represents a significant vote of confidence from a major value-oriented institutional investor.

Contextual Analysis

Filing Significance

• A Schedule 13G is filed by passive investors who own more than 5% of a company's stock. An amendment (13G/A) is required annually or more frequently if there are material changes to the ownership percentage. This filing updates the market on Pzena's position as of the end of Q3 2025.

Filer Context

• Pzena Investment Management is a global investment management firm known for its classic value investing approach. Their holdings are closely watched for indications of undervalued companies.

Company Context

• USANA Health Sciences develops and manufactures nutritional supplements, personal care, and wellness products. The holding by Pzena suggests the firm sees long-term value in USANA's business model and market position.

Risk Assessment

Risk Level: Low

Risk Factors

• The primary risk is a potential future sale by the institutional holder, which could create downward pressure on the stock price.
• The filing does not provide insight into the short-term performance expectations of the investor.

Market Considerations

• Investors should monitor future 13F and 13G filings from Pzena to track changes in their position.
• The overall performance of the health and wellness sector will continue to be a primary driver for USANA's stock price.

---

IMPORTANT DISCLAIMER: This analysis is for informational purposes only and is not intended as investment advice. The information presented is based on publicly available SEC filings and should not be construed as a recommendation to buy, sell, or hold any securities. Past performance does not guarantee future results. All investments carry risk, including the potential loss of principal. Please consult with a qualified financial advisor before making any investment decisions.

Analysis generated on 2025-10-14 | Data source: SEC EDGAR